Organisation paid for research Program year 2025 Source: CMS Open Payments

Skin Sciences PLLC

Neither a doctor nor a teaching hospital

Research payments

$2,714,820

715 payments

Through program year 2025, Skin Sciences PLLC is reported as receiving $2,714,820 in research payments, across 715 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$189,833	26
2024	Research	$780,265	286
2023	Research	$385,099	231
2022	Research	$146,736	20
2021	Research	$89,421	27
2020	Research	$430,471	61
2019	Research	$692,994	64

Breakdown

Who paid Research payments · program years 2019–2025

Bausch Health US, LLC $486,875 20 payments
Janssen Research & Development, LLC $365,855 18 payments
Incyte Corporation $351,284 28 payments
Almirall LLC $322,373 1 payment
Takeda Pharmaceuticals U.S.A., Inc. $225,460 24 payments
AbbVie, Inc. $186,842 33 payments
Sanofi US Services Inc. $175,510 14 payments
Pfizer Inc. $138,134 42 payments
Dermavant Sciences, Inc. $126,517 468 payments
Genzyme Corporation $92,666 9 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $365,855 18 payments
Seysara in the Treatment of Rosacea $322,373 1 payment
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $185,129 16 payments
M15-997 $178,182 30 payments
PD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell carcinoma-a window of opportunity trial $173,242 7 payments
Efficacy and Tolerability of Duobrii Lotion $146,371 1 payment
Efficacy and Safety of of Cabtreo Topical Gel in Treatment of Truncal Acne Vulgaris $119,280 3 payments
A Randomized Doubleblind Placebocontrolled Study to Demonstrate the Efficacy and Longterm Safety of Pf04965842 With Topical Corticosteroids in Adult Patients With Moderatetosevere Atopic Dermatitis $105,097 21 payments
POC - Atopic dermatitis $92,666 9 payments
Efficacy and safety of Arazlo lotion in the treatment of truncal acne vulgaris $84,600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.